Iron deficiency in pregnancy is a major public health problem that causes maternal complications. The objective of this randomized, controlled trial was to examine the bioavailability, efficacy, and safety of oral ferrous bisglycinate plus folinic acid supplementation in pregnant women with iron deficiency. Subjects (12−16 weeks of gestation, n = 120) were randomly allocated to receive oral iron as ferrous bisglycinate (equiv. iron 24 mg) in supplement form with folinic acid and multivitamins (test group, n = 60) or as ferrous fumarate (equiv. iron 66 mg iron, control group, n = 60) after breakfast daily. Iron absorption was assessed by measuring fasted serum iron levels at 1 and 2 h immediately after supplementation. Hematological biomarkers and iron status were assessed before intervention, and at 3 and 6 months. Side effects were monitored throughout the intervention. A significant increase in serum iron was seen in both groups (p < 0.001) during the bioavailability assessment; however, the test group increases were comparatively higher than the control values at each timepoint (p < 0.001). Similarly, both test and control groups demonstrated a statistically significant increases in hemoglobin (Hb) (p < 0.001), erythrocytes (p < 0.001), reticulocytes (p < 0.001), mean corpuscular volume (MCV) (p < 0.001), mean corpuscular hemoglobin (MCH) (p < 0.001), mean corpuscular hemoglobin concentration (MCHC) (p < 0.001), % transferrin saturation (p < 0.001), and ferritin (p < 0.001) at 3 and 6 months after supplementation. However, in all cases, the test group increases were numerically larger than the control group increases at each timepoint. The test intervention was also associated with significantly fewer reports of nausea, abdominal pain, bloating, constipation, or metallic taste (p < 0.001). In conclusion, ferrous bisglycinate with folinic acid as a multivitamin nutraceutical format is comparable to standard ferrous fumarate for the clinical management of iron deficiency during pregnancy, with comparatively better absorption, tolerability, and efficacy and with a lower elemental iron dosage.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8839493PMC
http://dx.doi.org/10.3390/nu14030452DOI Listing

Publication Analysis

Top Keywords

ferrous bisglycinate
16
folinic acid
16
iron deficiency
16
iron
13
bisglycinate folinic
12
test group
12
group increases
12
0001 corpuscular
12
0001
11
efficacy safety
8

Similar Publications

Article Synopsis
  • Many pregnant women hesitate to take oral iron supplements due to fears of gastrointestinal (GI) side effects, leading to a study comparing the effects of three different iron formulas on GI complaints in healthy pregnant women.* -
  • Two double-blind studies were conducted, involving a total of 482 women, to assess side effects like nausea, constipation, and black stools from different iron dosages and formulas during pregnancy.* -
  • Among the iron supplements tested, ferrous bisglycinate at 25 mg showed the least GI side effects, while higher doses of ferrous fumarate resulted in more constipation and black stools, indicating it might be the least preferable option for pregnant women.*
View Article and Find Full Text PDF

Structural changes and in vitro bioaccessibility of CPP-febisgly complexes: Dependence on iron load.

Food Chem

January 2025

School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China. Electronic address:

Article Synopsis
  • The study investigated the effects of casein phosphopeptides (CPP) and ferrous bisglycinate (FebisGly) on iron supplementation at different ratios (1:20, 1:10, 1:5 w/w).
  • Results showed that CPP significantly increased the bioaccessibility of FebisGly by 68.72% and altered its structure, enhancing antioxidant activity and creating a stable secondary structure.
  • CPP also improved the uniformity of particle size, increased viscoelasticity, slowed gastric emptying, and reduced irritation, paving the way for new strategies in iron supplementation.
View Article and Find Full Text PDF

Improvement of in vivo iron bioavailability using mung bean peptide-ferrous chelate.

Food Res Int

August 2024

Anhui Engineering Laboratory for Agro-products Processing, Anhui Agricultural University, Hefei 230036, China; Anhui Engineering Research Center of Functional Food for Plant Active Peptides, Hefei 230036, Anhui, China; Department of Food Science and Engineering, College of Tea and Food Science & Technology, Anhui Agricultural University, Hefei 230036, Anhui, China; Key Laboratory of Jianghuai Agricultural Product Fine Processing and Resource Utilization, Ministry of Agriculture and Rural Affairs, Anhui Engineering Research Center for High Value Utilization of Characteristic Agricultural Products, College of Tea & Food Science and Technology, Anhui Agricultural University, Hefei, China. Electronic address:

There is an increasing amount of research into the development of a third generation of iron supplementation using peptide-iron chelates. Peptides isolated from mung bean were chelated with ferrous iron (MBP-Fe) and tested as a supplement in mice suffering from iron-deficiency anemia (IDA). Mice were randomly divided into seven groups: a group fed the normal diet, the IDA model group, and IDA groups treated with inorganic iron (FeSO), organic iron (ferrous bisglycinate, Gly-Fe), low-dose MBP-Fe(L-MBP-Fe), high-dose MBP-Fe(H-MBP-Fe), and MBP mixed with FeSO (MBP/Fe).

View Article and Find Full Text PDF

Comparative evaluation of different oral iron salts in the management of iron deficiency anemia.

Daru

December 2024

Department of Pharmacology, School of Pharmacy, RK University, Rajkot, 360020, Gujarat, India.

Background: Anemia affects one-fourth of the world's population and is caused mostly by iron deficiency. Iron supplementation is the most essential strategy for preventing iron deficiency anemia. Conventional oral iron salts have many drawbacks such as poor absorption & bioavailability, and poor tolerability resulting in poor clinical outcomes.

View Article and Find Full Text PDF

Objective: To compare the effectiveness, compliance, and side effect profile between daily or three times weekly (TIW) oral iron supplementation regimens in treating iron deficiency nonanemia (IDNA) in National Collegiate Athletic Association (NCAA) Division 1 female track and field or soccer athletes.

Design: Prospective cohort study.

Setting: Division 1 collegiate athletics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!